Autologous dopaminergic neuron replacement cell therapy

Autologous dopaminergic neuron replacement cell therapy is a regenerative medicine strategy aimed at treating Parkinson's disease by restoring dopaminergic innervation in the brain (Schweitzer et al., 2020, NEJM). This approach involves reprogramming a patient's own somatic cells into induced pluripotent stem cells (iPSCs), which are then differentiated into midbrain dopaminergic progenitor cells for transplantation into the striatum (Takahashi, 2020, Nature). Once grafted, these cells are intended to mature into functional neurons that provide a physiological supply of dopamine, potentially alleviating motor symptoms and reducing reliance on exogenous levodopa. Because the cells are genetically identical to the recipient, this autologous method significantly reduces the risk of immune rejection and the need for long-term immunosuppression (Barker et al., 2017, Lancet Neurology). Clinical candidates like ANPD001 are currently being evaluated for their ability to integrate into neural circuits and improve patient quality of life. Key challenges include ensuring the purity of the cell product to prevent tumorigenicity and managing the risk of graft-induced dyskinesia.

Other names

Autologous iPSC-derived dopaminergic neuronsAutologous midbrain dopaminergic progenitor cellsPatient-derived dopaminergic cell replacementAutologous cell therapy for Parkinson's disease

Restoration of striatal dopamine levels through the transplantation and functional integration of patient-derived dopaminergic progenitor cells into the putamen.